Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer : Statement from the DEGRO working group prostate cancer.

Ghadjar P, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Höcht S, Hölscher T, Müller AC, Niehoff P, Pinkawa M, Sedlmayer F, Zips D, Wiegel T; Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and The Working Party Radiation Oncology of the German Cancer Society (DKG-ARO).

Strahlenther Onkol. 2020 Mar 12. doi: 10.1007/s00066-020-01598-9. [Epub ahead of print] Review.

PMID:
32166452
2.

IMPACT OF EARLY PROPHYLACTIC CRANIAL IRRADIATION WITH HIPPOCAMPAL AVOIDANCE ON NEUROCOGNITIVE FUNCTION IN PATIENTS WITH LIMITED DISEASE SMALL-CELL LUNG CANCER. A MULTICENTER PHASE II TRIAL (SAKK 15/12).

Vees H, Caparrotti F, Eboulet EI, Xyrafas A, Fuhrer A, Meier U, Mark M, Elicin O, Aebersold DM, Zwahlen DR, Finazzi T, Allal AS, Putora PM, Martucci F, Rudolf CB, Ribi K; Swiss Group for Clinical Cancer Research (SAKK).

Int J Radiat Oncol Biol Phys. 2020 Mar 3. pii: S0360-3016(20)30255-8. doi: 10.1016/j.ijrobp.2020.02.029. [Epub ahead of print]

PMID:
32142869
3.

A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland.

Panje CM, Lupatsch JE, Barbier M, Pardo E, Lorez M, Dedes KJ, Aebersold DM, Plasswilm L, Gautschi O, Schwenkglenks M; Swiss Group for Clinical Cancer Research (SAKK).

Ann Oncol. 2020 Apr;31(4):501-506. doi: 10.1016/j.annonc.2020.01.007. Epub 2020 Jan 16.

PMID:
32107097
4.

MET targeting: time for a rematch.

Koch JP, Aebersold DM, Zimmer Y, Medová M.

Oncogene. 2020 Apr;39(14):2845-2862. doi: 10.1038/s41388-020-1193-8. Epub 2020 Feb 7. Review.

PMID:
32034310
5.

Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer : Statement from the DEGRO working group on prostate cancer.

Beck M, Böhmer D, Aebersold DM, Albrecht C, Flentje M, Ganswindt U, Höcht S, Hölscher T, Müller AC, Niehoff P, Pinkawa M, Sedlmayer F, Zips D, Zschaeck S, Budach V, Wiegel T, Ghadjar P; Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party Radiation Oncology of the German Cancer Society (DKG-ARO).

Strahlenther Onkol. 2020 Feb;196(2):109-116. doi: 10.1007/s00066-019-01553-3. Epub 2019 Nov 29.

PMID:
31784804
6.

Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.

Nisa L, Francica P, Giger R, Medo M, Elicin O, Friese-Hamim M, Wilm C, Stroh C, Bojaxhiu B, Quintin A, Caversaccio MD, Dettmer MS, Buchwalder M, Brodie TM, Aebersold DM, Zimmer Y, Carey TE, Medová M.

Mol Cancer Ther. 2020 Feb;19(2):614-626. doi: 10.1158/1535-7163.MCT-18-1274. Epub 2019 Nov 19.

PMID:
31744898
7.

ProtRank: bypassing the imputation of missing values in differential expression analysis of proteomic data.

Medo M, Aebersold DM, Medová M.

BMC Bioinformatics. 2019 Nov 9;20(1):563. doi: 10.1186/s12859-019-3144-3.

8.

Influencing Factors on Radiotherapy Outcome in Stage I-II Glottic Larynx Cancer-A Multicenter Study.

Elicin O, Ermiş E, Oehler C, Aebersold DM, Caparrotti F, Zimmermann F, Studer G, Henke G, Adam L, Anschuetz L, Ozsahin M, Guckenberger M, Shelan M, Kaydıhan N, Riesterer O, Prestwich RJD, Spielmann T, Giger R, Şen M.

Front Oncol. 2019 Sep 20;9:932. doi: 10.3389/fonc.2019.00932. eCollection 2019.

9.

Benchmarking Monte-Carlo dose calculation for MLC CyberKnife treatments.

Mackeprang PH, Vuong D, Volken W, Henzen D, Schmidhalter D, Malthaner M, Mueller S, Frei D, Kilby W, Aebersold DM, Fix MK, Manser P.

Radiat Oncol. 2019 Sep 18;14(1):172. doi: 10.1186/s13014-019-1370-5.

10.

Adaptive step size algorithm to increase efficiency of proton macro Monte Carlo dose calculation.

Kueng R, Frei D, Volken W, Stuermlin F, M Stampanoni MF, Aebersold DM, Manser P, Fix MK.

Radiat Oncol. 2019 Sep 9;14(1):165. doi: 10.1186/s13014-019-1362-5.

11.

[Modern Treatment Concepts in Radiation Oncology].

Plasswilm L, Studer G, Aebersold DM, Zwahlen DR.

Ther Umsch. 2019 Sep;76(4):209-218. doi: 10.1024/0040-5930/a001086. Review. German.

PMID:
31498043
12.

Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.

Hoyle AP, Ali A, James ND, Cook A, Parker CC, de Bono JS, Attard G, Chowdhury S, Cross WR, Dearnaley DP, Brawley CD, Gilson C, Ingleby F, Gillessen S, Aebersold DM, Jones RJ, Matheson D, Millman R, Mason MD, Ritchie AWS, Russell M, Douis H, Parmar MKB, Sydes MR, Clarke NW; STAMPEDE Investigators.

Eur Urol. 2019 Dec;76(6):719-728. doi: 10.1016/j.eururo.2019.08.006. Epub 2019 Aug 23.

PMID:
31447077
13.

Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial.

Riesterer O, Ciernik IF, Stahel RA, Xyrafas A, Aebersold DM, Plasswilm L, Mahmut Ozsahin E, Zwahlen DR, Nackaerts K, Zimmermann F, Sabrina Stark L, Weder W, Krayenbuehl J; Swiss Group for Clinical Cancer Research (SAKK).

Radiother Oncol. 2019 Sep;138:121-125. doi: 10.1016/j.radonc.2019.05.024. Epub 2019 Jun 25.

PMID:
31252293
14.

Skin surface markers for stereotactic body radiation therapy of sternal metastasis.

Hemmatazad H, Schmidhalter D, Elicin O, Aebersold DM, Herrmann E.

Rep Pract Oncol Radiother. 2019 Jul-Aug;24(4):322-324. doi: 10.1016/j.rpor.2019.05.005. Epub 2019 May 30.

PMID:
31193944
15.

Metabolomics reveals tepotinib-related mitochondrial dysfunction in MET-activating mutations-driven models.

Poliaková M, Felser A, Pierzchala K, Nuoffer JM, Aebersold DM, Zimmer Y, Zamboni N, Medová M.

FEBS J. 2019 Jul;286(14):2692-2710. doi: 10.1111/febs.14852. Epub 2019 May 11.

PMID:
30993872
16.

Disease Control With Delayed Salvage Radiotherapy for Macroscopic Local Recurrence Following Radical Prostatectomy.

Shelan M, Odermatt S, Bojaxhiu B, Nguyen DP, Thalmann GN, Aebersold DM, Dal Pra A.

Front Oncol. 2019 Feb 28;9:12. doi: 10.3389/fonc.2019.00012. eCollection 2019.

17.

Impact of regular magnetic resonance imaging follow-up after stereotactic radiotherapy to the surgical cavity in patients with one to three brain metastases.

Bachmann N, Leiser D, Ermis E, Vulcu S, Schucht P, Raabe A, Aebersold DM, Herrmann E.

Radiat Oncol. 2019 Mar 14;14(1):45. doi: 10.1186/s13014-019-1252-x.

18.

Whole-ventricular irradiation for intracranial germ cell tumors: Dosimetric comparison of pencil beam scanned protons, intensity-modulated radiotherapy and volumetric-modulated arc therapy.

Correia D, Terribilini D, Zepter S, Pica A, Bizzocchi N, Volken W, Stieb S, Ahlhelm F, Herrmann E, Fix MK, Manser P, Aebersold DM, Weber DC.

Clin Transl Radiat Oncol. 2019 Jan 9;15:53-61. doi: 10.1016/j.ctro.2019.01.002. eCollection 2019 Feb.

19.

Comparison of contemporary staging systems for oropharynx cancer in a surgically treated multi-institutional cohort.

Elicin O, Broglie MA, Fankhauser N, Stoeckli SJ, Pasche P, Reinhard A, Bongiovanni M, Huber GF, Morand GB, Soltermann A, Arnold A, Dettmer MS, Arnoux A, Stauffer E, Espeli V, Martucci F, Aebersold DM, Giger R.

Head Neck. 2019 May;41(5):1395-1402. doi: 10.1002/hed.25574. Epub 2018 Dec 28.

PMID:
30593685
20.

Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase.

Orlando E, Aebersold DM, Medová M, Zimmer Y.

Cancer Lett. 2019 Feb 28;443:189-202. doi: 10.1016/j.canlet.2018.12.001. Epub 2018 Dec 11. Review.

PMID:
30550851
21.

Incidence of second primary cancers after radiotherapy combined with platinum and/or cetuximab in head and neck cancer patients.

Elicin O, Sermaxhaj B, Bojaxhiu B, Shelan M, Giger R, Rauch D, Aebersold DM.

Strahlenther Onkol. 2019 Jun;195(6):468-474. doi: 10.1007/s00066-018-1400-5. Epub 2018 Nov 21.

PMID:
30465265
22.

Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation.

Bojaxhiu B, Templeton AJ, Elicin O, Shelan M, Zaugg K, Walser M, Giger R, Aebersold DM, Dal Pra A.

Radiat Oncol. 2018 Nov 6;13(1):216. doi: 10.1186/s13014-018-1159-y.

23.

Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease.

Nisa L, Barras D, Medová M, Aebersold DM, Medo M, Poliaková M, Koch J, Bojaxhiu B, Eliçin O, Dettmer MS, Angelino P, Giger R, Borner U, Caversaccio MD, Carey TE, Ho L, McKee TA, Delorenzi M, Zimmer Y.

Mol Cancer Res. 2018 Dec;16(12):1912-1926. doi: 10.1158/1541-7786.MCR-18-0056. Epub 2018 Aug 14.

24.

A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).

Panje CM, Dedes KJ, Matter-Walstra K, Schwenkglenks M, Gautschi O, Siano M, Aebersold DM, Plasswilm L, Lupatsch JE; Swiss Group for Clinical Cancer Research (SAKK).

Radiother Oncol. 2018 Nov;129(2):257-263. doi: 10.1016/j.radonc.2018.07.017. Epub 2018 Aug 10.

PMID:
30104008
25.

Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy.

Malla B, Aebersold DM, Dal Pra A.

J Transl Med. 2018 Aug 13;16(1):223. doi: 10.1186/s12967-018-1592-6.

26.

Accuracy assessment of a potential clinical use of navigation-guided intra-operative liver metastasis brachytherapy-a planning study.

Herrmann E, Terribilini D, Manser P, Fix MK, Toporek G, Candinas D, Weber S, Aebersold DM, Loessl K.

Strahlenther Onkol. 2018 Nov;194(11):1030-1038. doi: 10.1007/s00066-018-1334-y. Epub 2018 Jul 18.

27.

Part 1: Optimization and evaluation of dynamic trajectory radiotherapy.

Fix MK, Frei D, Volken W, Terribilini D, Mueller S, Elicin O, Hemmatazad H, Aebersold DM, Manser P.

Med Phys. 2018 Jul 10. doi: 10.1002/mp.13086. [Epub ahead of print]

PMID:
29992587
28.

Part 2: Dynamic mixed beam radiotherapy (DYMBER): Photon dynamic trajectories combined with modulated electron beams.

Mueller S, Manser P, Volken W, Frei D, Kueng R, Herrmann E, Elicin O, Aebersold DM, Stampanoni MFM, Fix MK.

Med Phys. 2018 Jul 10. doi: 10.1002/mp.13085. [Epub ahead of print]

PMID:
29992574
29.

Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxia.

Glück AA, Orlando E, Leiser D, Poliaková M, Nisa L, Quintin A, Gavini J, Stroka DM, Berezowska S, Bubendorf L, Blaukat A, Aebersold DM, Medová M, Zimmer Y.

Oncogene. 2018 Jul;37(30):4181-4196. doi: 10.1038/s41388-018-0256-6. Epub 2018 May 2.

PMID:
29717265
30.

The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer.

Poliaková M, Aebersold DM, Zimmer Y, Medová M.

Mol Cancer. 2018 Feb 19;17(1):27. doi: 10.1186/s12943-018-0798-9. Review.

31.

Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy.

Ghadjar P, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Höcht S, Hölscher T, Sedlmayer F, Wenz F, Zips D, Wiegel T; Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party Radiation Oncology of the German Cancer Society (DKG-ARO).

Strahlenther Onkol. 2018 Jul;194(7):619-626. doi: 10.1007/s00066-018-1269-3. Epub 2018 Jan 30. Review.

PMID:
29383406
32.

Highly conformal combined radiotherapy with cisplatin and gemcitabine for treatment of loco-regionally advanced cervical cancer - a retrospective study.

Cihoric N, Tsikkinis A, Vlaskou Badra E, Glatzer M, Novak U, Scherz A, Shelan M, Soldatovic I, Yojena CKK, Aebersold DM, Lössl K.

Radiat Oncol. 2017 Dec 22;12(1):202. doi: 10.1186/s13014-017-0938-1.

33.

Independent Monte-Carlo dose calculation for MLC based CyberKnife radiotherapy.

Mackeprang PH, Vuong D, Volken W, Henzen D, Schmidhalter D, Malthaner M, Mueller S, Frei D, Stampanoni MFM, Dal Pra A, Aebersold DM, Fix MK, Manser P.

Phys Med Biol. 2017 Dec 19;63(1):015015. doi: 10.1088/1361-6560/aa97f8.

PMID:
29256450
34.

Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10.

Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Stein J, Hölscher T, Gut P, Polat B, Hildebrandt G, Müller AC, Putora PM, Papachristofilou A, Schär C, Dal Pra A, Biaggi Rudolf C, Wust P, Aebersold DM, Thalmann GN; Swiss Group for Clinical Cancer Research (SAKK).

Radiother Oncol. 2018 Feb;126(2):257-262. doi: 10.1016/j.radonc.2017.10.025. Epub 2017 Nov 3.

PMID:
29103826
35.

Correction for Aebersold et al., "Extracellular Signal-Regulated Kinase 1c (ERK1c), a Novel 42-Kilodalton ERK, Demonstrates Unique Modes of Regulation, Localization, and Function".

Aebersold DM, Shaul YD, Yung Y, Yarom N, Yao Z, Hanoch T, Seger R.

Mol Cell Biol. 2017 Aug 28;37(18). pii: e00322-17. doi: 10.1128/MCB.00322-17. Print 2017 Sep 15. No abstract available.

36.

Exosomes and Exosomal MicroRNAs in Prostate Cancer Radiation Therapy.

Malla B, Zaugg K, Vassella E, Aebersold DM, Dal Pra A.

Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):982-995. doi: 10.1016/j.ijrobp.2017.03.031. Epub 2017 Mar 27. Review.

PMID:
28721912
37.

Primary tumor volume delineation in head and neck cancer: missing the tip of the iceberg?

Elicin O, Terribilini D, Shelan M, Volken W, Mathier E, Dal Pra A, Aebersold DM, Fix MK, Manser P.

Radiat Oncol. 2017 Jun 20;12(1):102. doi: 10.1186/s13014-017-0838-4.

38.

Outcome of proximal esophageal cancer after definitive combined chemo-radiation: a Swiss multicenter retrospective study.

Herrmann E, Mertineit N, De Bari B, Hoeng L, Caparotti F, Leiser D, Jumeau R, Cihoric N, Jensen AD, Aebersold DM, Ozsahin M.

Radiat Oncol. 2017 Jun 14;12(1):97. doi: 10.1186/s13014-017-0834-8.

39.

Altered regulation of ERK1b by MEK1 and PTP-SL and modified Elk1 phosphorylation by ERK1b are caused by abrogation of the regulatory C-terminal sequence of ERKs.

Yung Y, Yao Z, Aebersold DM, Hanoch T, Seger R.

J Biol Chem. 2017 May 26;292(21):8852. doi: 10.1074/jbc.A117.105995. No abstract available.

40.

Biomechanical Modeling of Pterygium Radiation Surgery: A Retrospective Case Study.

Pajic B, Aebersold DM, Eggspuehler A, Theler FR, Studer HP.

Sensors (Basel). 2017 May 24;17(6). pii: E1200. doi: 10.3390/s17061200.

41.

PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.

Nisa L, Häfliger P, Poliaková M, Giger R, Francica P, Aebersold DM, Charles RP, Zimmer Y, Medová M.

Mol Cancer. 2017 May 22;16(1):93. doi: 10.1186/s12943-017-0660-5.

42.

T1-2 glottic cancer treated with radiotherapy and/or surgery.

Shelan M, Anschuetz L, Schubert AD, Bojaxhiu B, Dal Pra A, Behrensmeier F, Aebersold DM, Giger R, Elicin O.

Strahlenther Onkol. 2017 Dec;193(12):995-1004. doi: 10.1007/s00066-017-1139-4. Epub 2017 May 4.

PMID:
28474090
43.

Simultaneous optimization of photons and electrons for mixed beam radiotherapy.

Mueller S, Fix MK, Joosten A, Henzen D, Frei D, Volken W, Kueng R, Aebersold DM, Stampanoni MFM, Manser P.

Phys Med Biol. 2017 Jun 26;62(14):5840-5860. doi: 10.1088/1361-6560/aa70c5.

PMID:
28467321
44.

Is Dose-Intensified Salvage Radiation Therapy After Prostatectomy Beneficial?

Ghadjar P, Hayoz S, Zwahlen DR, Thalmann GN, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK).

J Clin Oncol. 2017 May 1;35(13):1490-1491. doi: 10.1200/JCO.2016.70.7265. Epub 2017 Jan 30. No abstract available.

PMID:
28135138
45.

External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26.

Herrmann E, Naehrig D, Sassowsky M, Bigler M, Buijsen J, Ciernik I, Zwahlen D, Pellanda AF, Meister A, Brauchli P, Berardi S, Kuettel E, Dufour JF, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK).

Radiat Oncol. 2017 Jan 13;12(1):12. doi: 10.1186/s13014-016-0745-0.

46.

In Regard to Pisansky et al.

Ghadjar P, Hayoz S, Zwahlen DR, Thalmann GN, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK).

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):438-439. doi: 10.1016/j.ijrobp.2016.10.019. No abstract available.

PMID:
28068252
47.

Current status and perspectives of interventional clinical trials for glioblastoma - analysis of ClinicalTrials.gov.

Cihoric N, Tsikkinis A, Minniti G, Lagerwaard FJ, Herrlinger U, Mathier E, Soldatovic I, Jeremic B, Ghadjar P, Elicin O, Lössl K, Aebersold DM, Belka C, Herrmann E, Niyazi M.

Radiat Oncol. 2017 Jan 3;12(1):1. doi: 10.1186/s13014-016-0740-5. Review.

48.

Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer.

Ghadjar P, Hayoz S, Genitsch V, Zwahlen DR, Hölscher T, Gut P, Guckenberger M, Hildebrandt G, Müller AC, Putora PM, Papachristofilou A, Stalder L, Biaggi-Rudolf C, Sumila M, Kranzbühler H, Najafi Y, Ost P, Azinwi NC, Reuter C, Bodis S, Khanfir K, Budach V, Aebersold DM, Thalmann GN; Swiss Group for Clinical Cancer Research (SAKK).

BJU Int. 2017 Nov;120(5B):E45-E51. doi: 10.1111/bju.13742. Epub 2017 Jan 19.

49.

Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer.

Francica P, Nisa L, Aebersold DM, Langer R, Bladt F, Blaukat A, Stroka D, Martínez MR, Zimmer Y, Medová M.

Clin Cancer Res. 2016 Nov 1;22(21):5322-5336. Epub 2016 May 16.

50.

Erratum to: Hypofractionated radiotherapy for localized prostate cancer.

Höcht S, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Hölscher T, Martin T, Sedlmayer F, Wenz F, Zips D, Wiegel T.

Strahlenther Onkol. 2016 Nov;192(11):830. No abstract available.

Supplemental Content

Loading ...
Support Center